The Experts below are selected from a list of 66663 Experts worldwide ranked by ideXlab platform
Michael J Morris - One of the best experts on this subject based on the ideXlab platform.
-
relapsing polychondritis in the department of defense population and review of the literature
Seminars in Arthritis and Rheumatism, 2012Co-Authors: Stephanie D Mathew, Daniel F Battafarano, Michael J MorrisAbstract:Objective The objective of this study was to characterize the clinical features of relapsing polychondritis (RPC) within the department of defense beneficiary population and determine the utility of echocardiography, imaging studies, and pulmonary function testing for diagnosis and monitoring disease. Methods We performed a retrospective Electronic Medical Record chart review of all patients diagnosed with RPC within the department of defense between January 2004 and December 2009. Results Thirty patients met McAdam's diagnostic criteria and an additional 13 met our criteria for partial RPC. Auricular chondritis (88%), inflammatory eye disease (57%), and arthritis (60%) were the most common clinical manifestations. Pulmonary involvement was seen in 16 (37%) patients. Methotrexate (42%) and corticosteroids (21%) were the most conventional therapies. Thirty (70%) patients had pulmonary function tests with flow volume loop abnormalities observed in 33%. Chest computed tomography was performed in 63%, with abnormalities in 48%. Abnormalities on echocardiography were observed in 12 of 25 (48%) patients. Conclusions The incidence, demographic data, and organ involvement in our RPC patients were similar to previous studies. The diagnosis of RPC was determined primarily on physical examination and symptom-driven diagnostic testing. There was no notable pattern by rheumatologists for monitoring the progression of tracheobronchial tree or large vessel involvement. Interpreting flow volume loops is recommended with pulmonary function testing to detect early laryngotracheal involvement. Computed tomography of the chest is also recommended to monitor for vascular and tracheobronchial tree involvement.
-
department of defense prostate cancer clinical trials consortium a new instrument for prostate cancer clinical research
Clinical Genitourinary Cancer, 2009Co-Authors: Michael J Morris, E M Basch, George Wilding, Maha Hussain, Michael A Carducci, Celestia S Higano, Philip W Kantoff, William OhAbstract:Background In 2005, the US department of defense, through the US Army Medical Research and Materiel Command, office of the Congressionally Directed Medical Research Programs, created a funding mechanism to form a clinical trials consortium to conduct phase I and II studies in prostate cancer. This is the first report of the Prostate Cancer Clinical Trials Consortium (PCCTC).
Edwin M Posadas - One of the best experts on this subject based on the ideXlab platform.
-
a randomized phase ii study of pazopanib in castrate sensitive prostate cancer a university of chicago phase ii consortium department of defense prostate cancer clinical trials consortium study
Prostate Cancer and Prostatic Diseases, 2012Co-Authors: James E Ward, Maha Hussain, Theodore Karrison, Gurkamal S Chatta, Daniel H Shevrin, Russell Z Szmulewitz, Peter H Odonnell, Walter M Stadler, Edwin M PosadasAbstract:A randomized, phase II study of pazopanib in castrate-sensitive prostate cancer: a University of Chicago Phase II Consortium/department of defense Prostate Cancer Clinical Trials Consortium study
William Oh - One of the best experts on this subject based on the ideXlab platform.
-
department of defense prostate cancer clinical trials consortium a new instrument for prostate cancer clinical research
Clinical Genitourinary Cancer, 2009Co-Authors: Michael J Morris, E M Basch, George Wilding, Maha Hussain, Michael A Carducci, Celestia S Higano, Philip W Kantoff, William OhAbstract:Background In 2005, the US department of defense, through the US Army Medical Research and Materiel Command, office of the Congressionally Directed Medical Research Programs, created a funding mechanism to form a clinical trials consortium to conduct phase I and II studies in prostate cancer. This is the first report of the Prostate Cancer Clinical Trials Consortium (PCCTC).
Maha Hussain - One of the best experts on this subject based on the ideXlab platform.
-
a randomized phase ii study of pazopanib in castrate sensitive prostate cancer a university of chicago phase ii consortium department of defense prostate cancer clinical trials consortium study
Prostate Cancer and Prostatic Diseases, 2012Co-Authors: James E Ward, Maha Hussain, Theodore Karrison, Gurkamal S Chatta, Daniel H Shevrin, Russell Z Szmulewitz, Peter H Odonnell, Walter M Stadler, Edwin M PosadasAbstract:A randomized, phase II study of pazopanib in castrate-sensitive prostate cancer: a University of Chicago Phase II Consortium/department of defense Prostate Cancer Clinical Trials Consortium study
-
department of defense prostate cancer clinical trials consortium a new instrument for prostate cancer clinical research
Clinical Genitourinary Cancer, 2009Co-Authors: Michael J Morris, E M Basch, George Wilding, Maha Hussain, Michael A Carducci, Celestia S Higano, Philip W Kantoff, William OhAbstract:Background In 2005, the US department of defense, through the US Army Medical Research and Materiel Command, office of the Congressionally Directed Medical Research Programs, created a funding mechanism to form a clinical trials consortium to conduct phase I and II studies in prostate cancer. This is the first report of the Prostate Cancer Clinical Trials Consortium (PCCTC).
Y Wang - One of the best experts on this subject based on the ideXlab platform.
-
comorbidity and economic burden among moderate to severe psoriasis and or psoriatic arthritis patients in the us department of defense population
Journal of Medical Economics, 2018Co-Authors: S Y Lee, Lin Xie, Y Wang, Neel Vaidya, Onur BaserAbstract:Aims: To examine the comorbidity and economic burden among moderate-to-severe psoriasis (PsO) and/or psoriatic arthritis (PsA) patients in the US department of defense (DoD) population.Materials an...
-
phase ii study of first line sagopilone plus prednisone in patients with castration resistant prostate cancer a phase ii study of the department of defense prostate cancer clinical trials consortium
British Journal of Cancer, 2012Co-Authors: Tomasz M Beer, David C Smith, A Hussain, M Alonso, Jue Wang, M Giurescu, K Roth, Y WangAbstract:Phase II study of first-line sagopilone plus prednisone in patients with castration-resistant prostate cancer: a phase II study of the department of defense Prostate Cancer Clinical Trials Consortium
